by Madaline Spencer | Jul 7, 2025
The U.S. Food and Drug Administration (FDA) has approved Gammagard Liquid ERC (immune globulin infusion) for patients ages two years and older with primary immunodeficiencies. Primary immunodeficiencies are a group of rare, genetic diseases affecting the immune...
by Madaline Spencer | Jul 7, 2025
Paolo Ghia, MD, PhD, Professor of Medical Oncology at Università Vita-Salute San Raffaele in Milan, Italy, discusses results from clinical trial testing ibrutinib plus venetoclax in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL)....
by Madaline Spencer | Jul 5, 2025
Marc Rothenberg, MD, of the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR), and Professor of Medicine at Cincinnati Children’s Hospital, gives an overview of eosinophilic esophagitis (EoE). CEGIR is part of the Rare Diseases...
by Madaline Spencer | Jul 3, 2025
The U.S. Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in Still’s disease. Still’s disease is a rare systemic inflammatory...
by Madaline Spencer | Jul 3, 2025
Krish Patel, MD, Medical Oncologist at Sarah Cannon Research Institute, discusses first results from a study evaluating CAR-T cell therapy for large B cell lymphoma (LBCL). LBCL is a form of non-Hodgkin lymphoma. Lymphomas occur when cells of the immune...
